subject: Aarkstore Enterprise--- Complete Guide To The 2009 Pprs, Nice & Other Pharmaceutical Cost Containm [print this page] In an otherwise volatile pharmaceutical world, 2009 has seen two notable and durable anniversaries, the implementation of the tenth re-negotiated Pharmaceutical Price Regulation Scheme in January and the tenth birthday of the National Institute for Health and Clinical Excellence in April. PPRS and NICE, are among abbreviations most widely recognised, but their structures, functions and ways of working are often less than fully understood.
Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the UK delivers what it says in the title. It provides in one place fully-researched, up-to-date information and interpretation on all the market access barriers facing pharmaceutical companies in the four countries that make up the United Kingdom.
The UK has a much bigger global impact in pricing and health technology assessment terms than its market size would suggest. It is a key lead-off one for launches. While accounting for less than 4% of world demand for prescription medicines, other countries that set prices with reference to those in the UK together account for 25% of that demand. Like them or hate them, the PPRS and NICE are original, well-established and influential models that governments and industry bodies elsewhere look to.
The report addresses:
The UKs complex decision-making processes for funding of medicines.
The procedures and outcomes of the three HTA bodies, NICE, SMC and AWMSG.
How and why the 2009 PPRS evolved in the way it did, and what this means for companies selling medicines to the NHS.
The pros and cons of joining the voluntary or alternative statutory scheme.
All the changes in the new PPRS and the prospects for the more novel but contentious parts, including flexible pricing, patient access schemes and generic substitution.
What jargon including end-of-life treatment, horizon scanning, NICE blight,OFT wedge outturn, QALY, safety value and top-up actually mean.
Other cost containment measures impacting on prescribers, patients and the distribution chain.
